Pasar al contenido principal

APROXIMACION A LOS MECANISMOS DE GANANCIA EXCESIVA DE PESO ASOCIADA A INSTI Y TAF EN PVV: DE LA INTERFERENCIA CON LA HOMEOSTASIS INGRESO-GASTO ENERGIA A LA ALTERACION DE LA BIOLOGIA ADIPOCITARIA

PI20/00137

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización HOSPITAL DE LA SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Lipodystrophy in HIV, Evolving Challenges and Unresolved Questions

  • Girlat, Marta|||0000-0001-7968-4190
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Quesada-López, Tania|||0000-0002-7818-4351
  • Cereijo, Rubén|||0000-0002-1108-230X
  • Villarroya, Francesc|||0000-0003-1266-9142
The advent of effective antiretroviral therapy in the mid-1990s, which successfully prevented the progression to AIDS in people living with HIV (PLWH), was associated with the appearance of the so-called HIV-associated lipodystrophy. This condition involved subcutaneous fat atrophy; abdominal fat hypertrophy; and, in some cases, lipomatosis. It was also associated with systemic metabolic disturbances, primarily insulin resistance and dyslipidemia. Following the replacement of certain antiretroviral drugs, particularly the thymidine-analog reverse transcriptase inhibitors stavudine and zidovudine, with less toxic alternatives, the incidences of lipoatrophy and lipomatosis significantly declined. However, lipodystrophy resulting from first-generation antiretroviral therapy does not always resolve after switching to newer agents. Although the widespread use of modern antiretroviral drugs-especially integrase strand transfer inhibitors and non-lipoatrophic reverse transcriptase inhibitors such as tenofovir alafenamide-has reduced the incidences of severe forms of lipodystrophy, these regimens are not entirely free of adipose tissue-related effects. Notably, they are associated with weight gain that resembles common obesity and can have adverse cardiometabolic consequences. Recent evidence also suggests the hypertrophy of specific fat depots, such as epicardial and perivascular adipose tissue, in PLWH on last-generation treatments, potentially contributing to increased cardiovascular risk. This evolving landscape underscores the persistent vulnerability of PLWH to adipose tissue alterations. While these morphological changes may not be as pronounced as those seen in classic HIV-associated lipodystrophy, they can still pose significant health risks. The continued optimization of treatment regimens and the vigilant monitoring of adipose tissue alterations and metabolic status remain essential strategies to improve the health of PLWH.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reduced circulating levels of CXCL14 are associated with cardiovascular damage in people living with HIV

  • Quesada-López, Tania|||0000-0002-7818-4351
  • Mestres-Arenas, Alberto
  • Prieto, Paula Florencia|||0000-0003-1978-758X
  • Mur, Isabel|||0000-0001-7660-8483
  • Hidalgo Pérez, José Alberto
  • Villarroya, Joan|||0000-0002-7859-1109
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Girlat, Marta|||0000-0001-7968-4190
  • Cereijo, Rubén|||0000-0002-1108-230X
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Guimarães, Mariana P.
  • Planavila, Anna
Combined antiretroviral therapy (cART) has improved quality of life of people living with HIV (PLWH). However, alterations in adiposity with concomitant cardiovascular disease (CVD) and circulating systemic disturbances reminiscent of the metabolic syndrome still occur. We recently identified chemokine C-X-C motif ligand 14 (CXCL14) as a brown adipokine involved in M2 macrophage migration to adipose tissues to promote energy expenditure and insulin sensitivity, also exerting cardioprotective actions. Here, we aimed to study CXCL14 regulation and potential association with CVD in PLWH. Serum levels of CXCL14 and adipocytokines of interest were quantified in cohort of 50 cART-treated PLWH and 38 age- and sex-matched controls (50.6 ± 10.1 years, 74.1 % males). Adipose biopsies were extracted for CXCL14 mRNA expression assessment using RT-qPCR. Cardiac computed tomography angiography with contrast-enhanced scan was used to determine atherosclerotic coronary burden, and multivariant models were used to integrate data. CXCL14 circulating levels and mRNA expression in subcutaneous fat were reduced in cART-treated PLWH, especially women. While no association with insulin resistance was observed, circulating CXCL14 negatively correlated with visceral adiposity and tumor necrosis factor alpha (TNFα), fibroblast growth factor 23 (FGF23) and phospholipase A2 Group VII (PLA2G7) levels, and with presence of noncalcified atheromatous plaque in PLWH. This reduction in CXCL14 levels and negative association with inflammation and visceral fat in cART-treated PLWH were reminiscent of its regulation in diabesity. Despite further research is needed, association of circulating CXCL14 with noncalcified atheromatous plaque can result in applications as a novel subclinical biomarker for CVD in PLWH.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Girlat, Marta|||0000-0001-7968-4190
  • Gavaldà i Navarro, Aleix|||0000-0001-8421-3174
  • Blasco-Roset, Albert|||0000-0002-4686-6075
  • Delgado-Anglés, Alejandro|||0000-0002-6996-6327
  • Gallego-Escuredo, José Miguel
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Cereijo, Rubén|||0000-0002-1108-230X
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Villarroya, Joan
Lipodystrophy is a major disturbance in people living with HIV-1 (PLWH). Several systemic alterations in PLWH are reminiscent of those that occur in ageing. It is unknown whether the lipodystrophy in PLWH is the consequence of accelerated ageing in adipose tissue. We compared systemic and adipose tissue disturbances in PLWH with those in healthy elderly individuals (~80 y old). We observed similarly enhanced expression of inflammation-related genes and decreased autophagy in adipose tissues from elderly individuals and PLWH. Indications of repressed adipogenesis and mitochondrial dysfunction were found specifically in PLWH, whereas reduced telomere length and signs of senesce were specific to elderly individuals. We conclude that ageing of adipose tissue accounts only partially for the alterations in adipose tissues of PLWH.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Quesada-López, Tania|||0000-0002-7818-4351
  • Villarroya, Joan
  • Cairó, Montserrat
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mateo, Maria Gracia
  • Mur, Isabel|||0000-0001-7660-8483
  • Corbacho, Noemí
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Girlat, Marta|||0000-0001-7968-4190
Aims: To assess the potential direct effects of the integrase strand-transfer inhibitors (INsTIs) dolutegravir, bictegravir, and raltegravir, drugs used as treatment for people living with human immunodeficiency virus (PLWH), on human adipose cells. Main methods: Drugs were added to the differentiation medium of human Simpson-Golabi-Behmel syndrome (SGBS) adipose cells and morphological adipogenesis was monitored for 10 days. Also, adipocytes were exposed to drugs following differentiation (day 14). The gene expression levels of selected adipogenesis markers, adipocyte metabolism markers, adipokines, and cytokines were determined by quantitative-reverse transcription polymerase-chain reaction. The release of adiponectin and leptin into the culture medium was measured using specific enzyme-linked immunosorbent assay, and release of interleukin-6 and chemokine (C[sbnd]C motif) ligand-2 using Multiplex assays. Key findings: Overall morphological adipogenesis was unaltered by INsTIs. The expression of adipogenesis marker genes (peroxisome proliferator-activated receptor-Ɣ and lipoprotein lipase) was slightly reduced in dolutegravir-treated differentiating adipocytes. Bictegravir repressed gene expression and the release of pro-inflammatory cytokines in differentiating adipocytes. Dolutegravir and raltegravir increased interleukin-6 gene expression, but only dolutegravir increased interleukin-6 release. Dolutegravir repressed adiponectin expression and release in differentiating adipocytes and had a similar but milder effect on leptin. Drug treatment of mature adipocytes reduced adiponectin gene expression in response to dolutegravir. Significance: The INsTIs studied do not have a significant effect on human adipose cell differentiation but exert distinct effects on gene expression and secretion of adipokines and cytokines. These findings will help understand and manage the effects of INsTI-containing treatments on body weight and metabolic dysregulation in PLWH.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function

  • Quesada-López, Tania|||0000-0002-7818-4351
  • Blasco-Roset, Albert|||0000-0002-4686-6075
  • Mestres-Arenas, Alberto
  • Prieto, P.
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Girlat, Marta|||0000-0001-7968-4190
  • Cereijo, R.
  • Domingo, J.C.
Combined antiretroviral therapy (cART) has been associated with increased body weight accompanied by metabolic alterations in people living with human immunodeficiency virus (PLWH). To gain insight into the combined effects of cART components on adipocyte dysfunction, we assessed whether and how treatment of human adipocytes with dolutegravir (DTG) and the nucleotide-analog reverse-transcriptase inhibitors (NRTIs), tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), alone and in combination, altered biological processes related to adipose tissue dysfunction. DTG, TAF, and TDF were applied to human Simpson-Golabi-Behmel syndrome (SGBS) adipose cells during differentiation (day 10) and ensuing differentiation (day 14). Expression of selected marker genes was determined by qPCR, the release of adipokines and inflammatory cytokines to the culture media was assessed, and cell respiration was measured. Adipogenesis was not altered by the combined treatment of human adipocytes. However, DTG at the highest dose repressed adipogenesis marker genes expression, and TAF and TDF appeared to mitigate this effect. DTG repressed the expression of adiponectin and the release of adiponectin and leptin in differentiating adipocytes, and these effects were mantained in combination with TAF and TDF. DTG plus TAF or TDF on human adipocytes enhanced inflammation and stress and increased the release of proinflammatory cytokines to the culture media. Together, our results show that combined therapy with these drugs can alter inflammation, cellular stress, and fibrosis in human adipocytes. These findings may improve our understanding and management of the effects of cART on body adiposity and metabolic dysregulation in PLWH.